Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 8/20 | 0.33 |
| ▸ | ACHE | P22303 | 8/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72861 | 0.85 | C5AR1 (0.38) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL62344 | 0.83 | ACHE (0.43) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL3818877 | 0.83 | ACHE (0.34) | C5AR1BCHEACHEHTTSMN1; SMN2 | |
| SCHEMBL3819803 | 0.81 | BCHE (0.33) | C5AR1BCHEACHE | |
| SCHEMBL3818386 | 0.81 | BCHE (0.33) | C5AR1BCHEACHE | |
| SCHEMBL3509166 | 0.81 | CCNT1 (0.36) | C5AR1BCHEACHECCNT1CDK9 | |
| SCHEMBL61672 | 0.81 | BCHE (0.35) | C5AR1BCHEACHECCNT1CDK9 | |
| SCHEMBL61126 | 0.80 | BCHE (0.35) | C5AR1BCHEACHECCNT1CDK9 | |
| SCHEMBL73579 | 0.80 | CCNT1 (0.36) | C5AR1BCHEACHECCNT1CDK9 | |
| SCHEMBL62161 | 0.79 | C5AR1 (0.40) | C5AR1BRD4BCHEACHEHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | claimed |
| EP-1745033-A4 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORP (US) | 2009-08-26 | — | — | EP | claimed |
| CN-1976918-A | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORP (US) | 2007-06-06 | — | — | CN | claimed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | claimed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| EP-1745033-A4 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORP (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| CN-1976918-A | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | C5AR1 3/4885PRMT5 1252/4885BRD4 1485/4885 |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C5AR1, C3AR1 | C5AR1 2/4885PRMT5 1026/4885BRD4 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.